The Medical Letter on Drugs and Therapeutics
Recombinant Human Antithrombin (ATryn)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the use of recombinant human antithrombin (rhAT; ATryn – Lundbeck) in patients with inherited antithrombin (AT) deficiency to prevent thrombosis during or after surgery or childbirth. The protein is produced in the milk of transgenic goats carrying a copy of the human cDNA for AT. This is the first US drug approval for a protein produced by a transgenic animal. ATryn has been used in Europe since 2006.

ANTITHROMBIN DEFICIENCY — AT is the major physiological inhibitor of the coagulation factors thrombin and Factor Xa (FXa). Inherited antithrombin deficiency is a prothrombotic genetic disorder, with an incidence of 1 in 500 to 1 in 5000. Patients with AT deficiency are at a much higher risk than the general population for venous thromboembolism. Patients with inherited AT deficiency may require lifelong anticoagulation, typically with a vitamin K antagonist such as ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Recombinant Human Antithrombin (ATryn)
Article code: 1323c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian